Sign In
Buy NVTA
$0.0190
+0 (+0%)
At Close: May 13, 2024
Outcomes4Me Partners with Invitae to Offer Genetic Testing to Breast Cancer Patients
02:35pm, Monday, 11'th Oct 2021
BOSTON--(BUSINESS WIRE)-- #breastcancer--Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae
Can This Stock Grow Despite a COVID Testing Decline?
06:20am, Tuesday, 05'th Oct 2021
Fulgent has capitalized on COVID-19 testing, but even though this segment of its business might slow, there are plenty of reasons to own the company.
3 Sinking Stocks Cathie Wood Keeps Buying Anyway
06:14am, Sunday, 03'rd Oct 2021
ARK Invest's founder and CEO isn't shy about averaging down on her favorite growth stocks.
New Study Highlights the Value of Genetic Testing to Guide Clinical Management and Improve Outcomes for Epilepsy Patients
12:15pm, Saturday, 25'th Sep 2021
SAN FRANCISCO, Sept. 25, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today presented research demonstrating that genetic findings informed clinical management chang
Cathie Wood Goes Bargain Shopping: 3 Sinking Stocks She Keeps Buying
06:21am, Monday, 20'th Sep 2021
The CEO of ARK Invest is averaging down on these compelling life-science stocks.
Invitae Corporation (NVTA) Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)
03:34pm, Tuesday, 14'th Sep 2021
Invitae Corporation (NVTA) Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)
As Invitae pays $325 million to buy Ciitizen, should you invest in NVTA shares?
03:28pm, Tuesday, 07'th Sep 2021
On Tuesday, Invitae Corp (NYSE:NVTA) shares edged slightly lower after announcing the purchase of health tech company Ciitizen in a cash and stock deal worth $325 million. The company will pay $125 mi
Invitae Strengthens Health Data Platform With Ciitizen Acquisition
11:01am, Tuesday, 07'th Sep 2021
Invitae Corp (NYSE: NVTA) has agreed to acquire consumer health technology company Ciitizen for $325 million in a bid to make it easier for patients to collect their genomic and clinical informatio
Invitae to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
07:30am, Wednesday, 01'st Sep 2021
SAN FRANCISCO, Sept. 1, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in a virtual f
Cathie Wood Stocks: What Names Is ARK Invest CEO Buying Now?
01:09pm, Tuesday, 17'th Aug 2021
Cathie Wood continues to pick up stocks through her ARK Invest ETFs and we're taking a look at some of their top investments for Tuesday. The post Cathie Wood Stocks: What Names Is ARK Invest CEO Buyi
Report: Exact Sciences (EXAS) Approached Invitae (NVTA) For Merger Offer
08:27am, Saturday, 07'th Aug 2021
EXACT Sciences Corporation (NASDAQ: EXAS) reportedly approached Invitae Corp (NYSE: NVTA) for a potential merger. These are the details.
Why Did Invitae Stock Fall 17% in July?
06:02pm, Friday, 06'th Aug 2021
This genetic testing innovator slumped along with other genomics stocks last month.
Invitae Stock Jumps As Higher Test Volume More Than Doubles Q2 Topline, Raises FY21 Sales Outlook
09:33am, Wednesday, 04'th Aug 2021
Invitae Corporation (NYSE: NVTA), after the close of the market on Tuesday, reported its second-quarter revenues of $116.3 million, +152% Y/Y, exceeding the consensus Wall Street estimate of $108.3
NVTA Stock Price Increases Over 8% Pre-Market: Why It Happened
08:47am, Wednesday, 04'th Aug 2021
The stock price of Invitae Corp (NYSE: NVTA) increased by over 8% pre-market. This is why it happened.
Invitae Corporation's (NVTA) CEO Sean George on Q2 2021 Results - Earnings Call Transcript
10:53pm, Tuesday, 03'rd Aug 2021
Invitae Corporation's (NVTA) CEO Sean George on Q2 2021 Results - Earnings Call Transcript
